Adefovir and Lamivudine Combination Therapy in Patients with Entecavir-Resistant Chronic Hepatitis B: Antiviral Responses and Evolution of Mutations
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Lee, Hyun Jung | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Kim, Chang Wook | - |
dc.contributor.author | Lee, Chang Don | - |
dc.contributor.author | Park, Sang Hoon | - |
dc.contributor.author | Lee, Myung Seok | - |
dc.contributor.author | Park, Choong Kee | - |
dc.contributor.author | Chae, Hee Bok | - |
dc.contributor.author | Kim, Moon Young | - |
dc.contributor.author | Baik, Soon Koo | - |
dc.contributor.author | Kim, Yun Soo | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.contributor.author | Il Lee, Jung | - |
dc.contributor.author | Hong, Sun Pyo | - |
dc.contributor.author | Um, Soon Ho | - |
dc.date.accessioned | 2021-09-05T17:23:47Z | - |
dc.date.available | 2021-09-05T17:23:47Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0300-5526 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/101206 | - |
dc.description.abstract | Objective: This study was designed to prospectively evaluate the antiviral responses and evolution of resistance mutations during adefovir (ADV) plus lannivudine (LMV) therapy in patients with entecavir (ETV)-resistant hepatitis B virus (HBV) infection. Methods: Twenty chronic hepatitis B (CHB) patients who had been receiving ETV for more than 6 months and developed virologic breakthrough due to ETV resistance were consecutively enrolled. Results: Patients received ADV plus LMV therapy for 12 months. The baseline mean serum HBV DNA level was 5.59 +/- 1.28 log(10) IU/ml. The rtT184L/1/A/F (50%), rtS202G (25%) and mixed ETV-resistant mutations (25%) were detected at enrollment. The mean reduction in serum HBV DNA levels from baseline to 12 months was -2.3 +/- 1.06 log(10) IU/ml (p < 0.001). Seventeen patients were followed up for the full 12 months, and complete virologic response (HBV DNA <20 IU/ml) was observed in 4 patients (23.5%). Among the remaining 13 patients who still had detectable HBV DNA, 7 patients showed disappearance of ETV-resistant mutations or reduction of the proportion of ETV-resistant mutants. An ADV- and LMV-resistant mutant (rtA181T) emerged in 2 patients (11.7%). Conclusions: ADV plus LMV combination therapy suppresses ETV-resistant mutants in the viral population and significantly reduces serum HBV DNA levels in ETV-resistant CHB patients. (C) 2014 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | RESCUE THERAPY | - |
dc.subject | VIRUS | - |
dc.subject | SUBSTITUTIONS | - |
dc.subject | MONOTHERAPY | - |
dc.subject | DIPIVOXIL | - |
dc.subject | EFFICACY | - |
dc.subject | OUTCOMES | - |
dc.subject | UPDATE | - |
dc.subject | DNA | - |
dc.title | Adefovir and Lamivudine Combination Therapy in Patients with Entecavir-Resistant Chronic Hepatitis B: Antiviral Responses and Evolution of Mutations | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.identifier.doi | 10.1159/000360399 | - |
dc.identifier.scopusid | 2-s2.0-84928103941 | - |
dc.identifier.wosid | 000340812800001 | - |
dc.identifier.bibliographicCitation | INTERVIROLOGY, v.57, no.5, pp.239 - 247 | - |
dc.relation.isPartOf | INTERVIROLOGY | - |
dc.citation.title | INTERVIROLOGY | - |
dc.citation.volume | 57 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 239 | - |
dc.citation.endPage | 247 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | RESCUE THERAPY | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | SUBSTITUTIONS | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | DIPIVOXIL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | UPDATE | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordAuthor | Adefovir | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Entecavir | - |
dc.subject.keywordAuthor | Lamivudine | - |
dc.subject.keywordAuthor | Resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.